| 刘 红.思连康对肝硬化血浆内毒素影响的研究[J].,2006,6(1):53-54 |
| 思连康对肝硬化血浆内毒素影响的研究 |
| Effect of Silico on Plasma Endotoxin of Patients with Liver Cirrhosis |
| |
| DOI： |
| 中文关键词: 思连康 肝硬化 患者 大鼠 血浆内毒素 |
| 英文关键词: Silico Liver cirrhosis Patient Rat Plasma endotoxin |
| 基金项目: |
|
| 摘要点击次数: 721 |
| 全文下载次数: 456 |
| 中文摘要: |
| 目的: 探讨益生菌制剂思连康治疗肝硬化内毒素血症的作用机制。方法: 采用大鼠肝硬化模型, 其中治疗组予以思连
康液灌胃治疗, 共8 周, 检测治疗组及对照组血浆内毒素指标; 并选取70 例肝硬化ChildPugh 分级为B 级的患者, 其中治疗组口服
思连康( 每次两粒, 每日三次) 3 周, 观察治疗前后血浆内毒素变化。结果: 思连康治疗组的肝硬化大鼠及患者血浆内毒素均明显
低于对照组( p< 0. 05) 。结论: 思连康能明显降低肝硬化患者血浆内毒素水平, 可作为肝硬化患者的辅助用药。 |
| 英文摘要: |
| Objective: To investigate the effect of Silico capsule on the levels of plasma endotoxin( PET) in rats and patients with liver cirrhosis(
LC) . Methods: 44 rats were induced into live cirrhosis models by injecting CCl4 every 3 days for 8 weeks. 70 patients with cirrhosis of
Child- Pugh B stage were observed, and 35 patients were treated by Silico capsule( 2capsules, three times a day) orally for three weeks. Plasma
endotoxon was detected by tachypleus amebocyte lysate ( TAL) before and after the therapy . Results: The levels of endotoxin in the treatment
groups were significantly lower than those in control group( P< 0. 05) . Conclusion: Silico could reduce the level of endotoxin in the plasma of patients
with liver cirrhosis , which could be used for routine auxiliary therapy of LC patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
